Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited Operating Cash Flow for the year ending March 31, 2024: USD 27.62 M

Marksans Pharma Limited Operating Cash Flow is USD 27.62 M for the year ending March 31, 2024, a -4.37% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Marksans Pharma Limited Operating Cash Flow for the year ending March 31, 2023 was USD 28.89 M, a 120.97% change year over year.
Marksans Pharma Limited Operating Cash Flow for the year ending March 31, 2022 was USD 13.07 M, a -46.45% change year over year.
Marksans Pharma Limited Operating Cash Flow for the year ending March 31, 2021 was USD 24.41 M, a -12.38% change year over year.
Marksans Pharma Limited Operating Cash Flow for the year ending March 31, 2020 was USD 27.86 M, a 606.71% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Health Care
Industries Pharmaceuticals

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years